News Preview
STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug
Life Biosciences has provided an update on its glaucoma study, reporting that three patients have received a single injection of its experimental cellular reprogramming drug with no serious adverse events.
Want to stay up to date with the world events at sea or at home?
Explore Navvyx News - the best News app for seafarers.